Lipocine Inc. (LPCN)
Oxford Ledge is still expanding full research coverage of LPCN. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Lipocine develops oral medications using proprietary delivery technology, with its approved product TLANDO licensed to multiple partners and a clinical pipeline targeting CNS and other conditions.
SEC filings
- 8-K Other material event; Financial statements and exhibits 2026-06-12
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-04
- 8-K Other material event; Financial statements and exhibits 2026-06-04
- 8-K Other material event; Financial statements and exhibits 2026-05-26
- 8-K Other material event; Financial statements and exhibits 2026-05-19
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for LPCN. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open LPCN in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.